The conformationally restricted glutamate analogues, 3-alkyl-1-amino-2cyclopentene-1,3-dicarboxylates and N-alkylated analogues have been prepared in a regioselective and diastereoselective manner. From the biological studies of the 3alkylated analogues, compound 13b was found to be the most potent antagonist (IC 50 7.7 M) at mGluR2. Amongst the N-alkylated analogues, compound 20 was found to be a partial agonist (EC 50 9.5 M) and as well as an antagonist (IC 50 47 M) at mGluR2.
Introduction
L-Glutamate (Glu) is the principal excitatory amino acid (EAA) neurotransmitter in the mammalian central nervous system (CNS) and operates through two main types of glutamate receptors. 1 Those which form ligand-gated cation channels (ionotropic glutamate receptors, iGluRs) and those which are coupled via G-protein to intercellular enzyme systems which influence the production of second messengers (metabotropic glutamate receptors, mGluRs). 2 Both iGluRs and mGluRs play crucial roles in the healthy, as well as the diseased CNS and these receptors are therefore potential targets for therapeutic intervention. 3 Considerable research efforts have been focused upon the development of selective agonists and antagonists for iGluRs and mGluRs. 4 A variety of cyclic, conformationally restricted glutamate analogues have been prepared in laboratories around the world but only a few are highly potent and sub-type selective. One such compound is the conformationally restricted glutamate analogue, (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid [(1S,3R)-ACPD] 1, which selectively activates metabotropic glutamate receptors (mGluRs) over the ionotropic type. (1S,3R)-ACPD 1 however is not selective for the individual eight mGluR subtypes. 5 While its diastereomer (1S,3S)-ACPD 2 is more potent and selective at mGluR2 (EC 50 1.2 M) than at other subtypes. 6 Figure 1 . Conformationally restricted glutamate analogues.
We previously reported the synthesis and biological activities of the conformational restricted cyclopentenyl-glutamate compound (S)-3, the dehydro-analogue of APCD. It was found to be an agonist at mGluR5 (EC 50 18 M) and mGluR2 (EC 50 45 M) receptors. 7 We also reported the synthesis of the 4-phenyl substituted derivative, rac-4, and its aryl substituted derivatives. Compound rac-4 is a selective antagonist at mGluR2 with modest activity with an IC 50 value of 32 M. 8 In order to further understand the SAR of the derivatives of rac-3, we aimed to synthesise its 3-alkylated and N-alkylated derivatives and investigate their biological activities.
The synthesis of the 3-alkylated compounds can be achieved by regioselective deprotonation at the γ-position of the α,β-unsaturated ester moiety of protected derivatives of rac-3 by a strong base to generate the corresponding extended enolate which undergoes regioselective alkylation at the -position to give -alkylated products 5 (Scheme 1). 9 Scheme 1. Alkylation of α,β-unsaturated ester.
We report here the regioselective and diastereoselective synthesis of 3-alkylated and N-alkylated derivatives of (S)-3. The biological activities of these compounds as agonists and antagonists at mGluR2 will also be discussed.
Results and discussion

Synthesis of compounds
Cyclopentenyl derivatives
Racemates 9a-d and their diastereoisomers 10a-d were obtained, according to Scheme 2. Treating the known racemate 6 7 with two equivalent of KN(TMS) 2 at -78 o C, followed by the addition of alkylating agents gave exclusively the -alkylated products 7 and 8 as the major and minor products, respectively. These outcomes concurred with the works reported by Katzenellenbogen et al, on the -alkylation of lithium dienolates derived from carbonyl esters. 10 The ratio of the isolated diastereoisomers 7 and 8 was determined by HPLC analysis, to be within the range of 8:2. 1 H NMR spectroscopic analysis of the two diastereomers, such as 7a and 8a
indicated that the major diastereomer 7a exhibited a H-4 resonance ( 5.89, d, J = 4. 2 Hz) and H-5 resonance ( 5.71, d, J = 4. 2 Hz) . The CH 3 -3 resonance at  1.49 of the major isomer 7a appeared more downfield than the corresponding resonance ( 1.32) of the minor isomer 8a. The relative stereochemistry of 7a was determined from NOESY experiments that showed significant cross-peaks between the signal for H-(Ar) and H-2, H-2 and H-(CH 3 -3) and that for H-(Ar) and H-(CH 3 -3). These cross-peaks are consistent with the cis orientation of the two carboxyl groups (Fig. 2) . The relative stereochemistries of the compounds, 8a, 8b and 7c were further unequivocally determined by X-ray structure analysis (Figs. 3-5). 11 Suitable crystals for X-ray analysis of compounds 8a, 8b and 7d were grown from a mixture of ethyl acetate and hexane. Acid hydrolysis of 7a-d and 8a-d under similar conditions gave the hydrochloride salts of 9a-d and 10a-d, respectively in acceptable yields (Table 2) . 
Cyclopentyl derivatives
The racemic cyclopentyl derivatives, 13 and 14, were synthesised, according to Scheme 3. Removal of diphenyl methylene group from 7 and 8 by a mild acid hydrolysis followed by hydrogenation proceeded smoothly to give 11 and 12, respectively, in good yields.
Acid hydrolysis of 11a-c and 12c gave the hydrochloride salts of 13a-c and 14c, respectively ( Table 3) . The relative stereochemistry of compound 18 was determined by NOESY experiments that showed significant cross peaks between the signal for H-3 and H-2
and that for H-2 and H-(CH 3 ). These confirmed the cis orientation of the two carboxyl groups ( Fig. 7 ). Reduction of ,-unsaturated esters and other electron deficient alkenes using magnesium metal in dry methanol has been described by us and others to be a selective and efficient method to provide the desired cis 18 as the major product. 8, [12] [13] [14] The cis orientation of the two carboxylic groups in 18 is considered to be significant structural features for activities. 6 The selectivity observed in the magnesium-methanol reduction of compound 16 might be due to the formation of the Mg(II) complex B, as shown in Figure   8 , which upon stereoselective protonation would give compound 18 as the major product. 
N-alkylated analogues
The racemic N-alkylated compounds 22a-e were obtained according to Scheme 5, the imine intermediates 21a-e were obtained by treating the known 15 8 with various aldehydes in dry THF in the presence of powdered molecular sieves, then followed by the reduction in the presence of NaBH 3 CN and acetic acid, in methanol to afford 21a-e in acceptable yields. Acid hydrolysis of 21a-e provided the hydrochloride salts of compounds 22a-e in high yields (Table 4 ). ]GTPS binding assay on membranes from these cells. 5 The results for the agonist and antagonist activities are summarised in Table 5 . Three compounds, namely 9a, 17 and 20 were found to be mGlu2 agonists.
Compound 17 was shown to exhibit mGluR2 agonism in the adenyl cyclase assay, with the potency of 3 M with an E max of 51% of the maximal glutamate response. However, the agonist activity of 17 was not confirmed in the [ 35 S]GTPS binding experiment, where this compound was expected to activate radioligand binding. Compound 17 was also shown to have inhibitory activity at the AMPA receptor in a glycine binding assay with an IC 50 value of 6.8 M (data is not shown). 13 The most active agonist in this series was 20 with a potency of EC 50 9.5 M and an E max of 34% of the maximal glutamate response. This compound also had inherent partial antagonist activity with an IC 50 of 47 M. The concentration-response curves illustrated that compound 20 is a partial agonist and as well as antagonist at mGluR2 receptors ( Fig.   9 ). Only one compound in this series, namely 22c, was found to be an inhibitor at the glycine site of the NMDA receptor with an IC 50 of 1.9 M (data is not shown), as measured in rat cortical membranes by radio-ligand binding.
The other synthesised compounds in this series were found to be inactive on the agonist as well as a partial antagonist. This structural feature was also found important in rac-4 and its active analogues and the well-known (1S,3S)-ACPA 6 . In summary, our results reveal that the ring flexibility and the cis orientation of the two carboxylic groups appear to be important structural features for activities at the mGluR2 receptor.
Conclusions
In conclusion, through this undertaking we have successfully prepared 3-alkylated and N-alkylated derivatives of rac-3 in a regioselective and diastereoselective manner. In this series of compounds, we have discovered a number of novel mGluR2 agonists and antagonists with potency in the low M range. Although, the conclusive structural activity relationship remains complex, we have however gained a clearer understanding of some of the key structure features required for a selective antagonist at mGluR2.
Experimental
Chemistry
Solvents and reagents were purchased from commercial sources and used without further purification unless otherwise stated. Unless specified, all NMR spectra were recorded at 
(1R*,3R*)-3-Ethyl 1-methyl 1-(diphenylmethyleneamino)-3-methylcyclopent-4-
ene-1,3-dicarboxylate (7a)
To a solution of compound 6 (0.552 g, 1.46 mmol) in dry THF (12 mL) at -78 o C was added a solution of KN(TMS) 2 (2.5 equiv., 7.3 mL, 3.66 mmol, 0.5 M in THF). After stirring for 1 h, a solution of methyl iodide (10 equiv., 0.9 mL, 14.6 mmol) in dry THF (2 mL) was added drop wise to the mixture and the stirring continued for another 1 h. The reaction mixture was allowed to warm to RT over 1 h then was diluted with a saturated aqueous solution of NaCl, and then extracted with ether. The combined organic extracts were dried over MgSO 4 and the solvent was removed to give a dark yellow residue which was purified by column chromatography (ethyl acetate/petroleum spirit, 1:9) to give a mixture of diastereomers (54%) in the ratio of 8:1 as determined by 1 
(1R*,3S*)-3-Ethyl 1-methyl 1-(diphenylmethyleneamino)-3-methylcyclopent-4-ene-
1,3-dicarboxylate (8a)
Minor isomer 8a, a yellow solid (34 mg, 6% 
General procedure for alkylation of 6
To a solution of compound 6 (0.552 g, 1.46 mmol) in dry THF (12 mL) at - 
General hydrolysis procedure for 7 and 8
Compound 7a (0.270 g, 0.70 mmol) in 10% aq. HCl (3 mL) was heated at 80 o C for 16 h.
After cooling, the reaction mixture was diluted with water (2 mL) and washed with ether (5 mL). The water was removed under reduced pressure to give the HCl salt of 9a as a white solid (0.133 g, 86%).
(1R*,3R*)-1-Amino-3-methylcyclopent-4-ene-1,3-dicarboxylic acid (9a)
A white solid (0.133 g, 86%). 1 
(1R*,3S*)-1-Allyl-3-aminocyclopent-4-ene-1,3-dicarboxylic acid (10b)
A pale yellow solid (22.1 mg, 100%). 1 
(1R*,3S*)-1-Amino-3-benzylcyclopent-4-ene-1,3-dicarboxylic acid (10c)
A white solid (29.0 mg, 98%). 1 
(1R*,3R*)-1-Amino-3-(3-phenylpropyl)cyclopent-4-ene-1,3-dicarboxylic acid (9d)
A white solid (37.3 mg, 63%). 1 
(1R*,3S*)-1-Amino-3-(3-phenylpropyl)cyclopent-4-ene-1,3-dicarboxylic acid (10d)
A white solid (22.7 mg, 76%). 1 
Representative procedure for preparation of rac-11 or rac-12
To a stirred solution of compound 7a (0.165 g, 0.422 mmol) in diethyl ether (2 mL 
(1S*,3S*)-3-Ethyl 1-methyl 1-amino-3-propylcyclopentane-1,3-dicarboxylate (11b)
A yellow oil (97.5 mg, 94%). 1 
(1S*,3R*)-3-Ethyl 1-methyl 1-amino-3-benzylcyclopentane-1,3-dicarboxylate (11c)
A yellow oil (79.0 mg, 66%). 1 
(1S*,3R*)-3-ethyl 1-methyl 1-amino-3-propylcyclopentane-1,3-dicarboxylate (12b)
A yellow oil (6.2 mg, 93%). 1 
(1S*,3S*)-3-Ethyl 1-methyl 1-amino-3-benzylcyclopentane-1,3-dicarboxylate (12c)
A yellow oil (43.3 mg, 70%). 1 
Representative procedure hydrolysis of rac-11 and rac-12
Compound 
(1S*,3S*)-1-Amino-3-propylcyclopentane-1,3-dicarboxylic acid (13b)
A white solid (77.6 mg, 99%). 1 
Rac-3-Ethyl 1-methyl 1-(dimethylamino)cyclopent-3-ene-1,3-dicarboxylate (16)
To a solution of compound 15 (1.17 g, 5.48 mmol) in CH 3 CN (30 mL) was added a solution of formaldehyde (40% aq., 11.5 mL, 13.7 mmol) and NaCNBH 3 (0.92 g, 14.6 mmol). After 20 min of stirring, the pH of the reaction mixture was adjusted to pH = 4, by addition of acetic acid. The reaction mixture was left to stir at RT overnight. The mixture was diluted with a saturated aqueous solution of Na 2 CO 3 (30 mL). The resulting solution was extracted twice with ethyl acetate (2 × 30 mL). The combined extracts were washed with a saturated solution of NaCl (30 mL) and dried over K 2 CO 3 . The solvent was removed under reduced pressure to give a yellow oil, which was purified by column chromatography (flash silica, ethyl acetate/light petroleum (1:1)) to give compound 16
(1.14 g, 86%) as a yellow oil. 1 242.1387.
Rac-1-(Dimethylamino)cyclopent-3-ene-1,3-dicarboxylic acid (17)
Compound 16 (0.100 g, 0.415 mmol) in 10% aq. HCl (2 mL) was heated at 80 o C for 16 h. After cooling, the reaction mixture was diluted with water (2 mL) and washed with ether (5 mL). The water was removed under reduced pressure to give the HCl salt of 17 as a white solid (95.8 mg, 96%). 1 
General procedure for preparation of compound 21
To a solution of compound 15 (0.470 g, 2.22 mmol) in dry THF (10 mL) was added the appropriate aldehyde (2.22 mmol) and powdered 5Å molecular sieves (2-3 g). The reaction mixture was left to stir at RT. Upon completion, the reaction mixture was filtered through a pad of celite. THF was removed under reduced pressure to give a yellow oil which was diluted with dry methanol (12 mL). To the resulting solution was added NaCNBH 3 (0.280 g, 4.44 mmol). The pH of the reaction mixture was adjusted to pH = 4, by the addition of acetic acid. The reaction mixture was left to stir at RT for 20 h. The mixture was diluted with H 2 O (20 mL) and made basic by adding solid Na 2 CO 3 . The aqueous solution was extracted with CH 2 Cl 2 and the combined extracts were dried over K 2 CO 3. The solvent was removed to give a yellow oil which was purified by column chromatography (MeOH/ethyl acetate, 1:10).
Rac-3-Ethyl 1-methyl 1-(benzylamino)cyclopent-3-ene-1,3-dicarboxylate (21a)
A yellow oil (0.538 g, 80%), 1 
Rac-3-Ethyl 1-methyl 1-(pyridin-2-ylmethylamino)cyclopent-3-ene-1,3dicarboxylate (21b)
A yellow oil (0.436 g, 80%), 1 
Rac-3-Ethyl 1-methyl 1-(pyridin-3-ylmethylamino)cyclopent-3-ene-1,3dicarboxylate (21c)
A yellow oil (0.267 g, 58%), 1 
Rac-3-Ethyl 1-methyl 1-(3-hydroxybenzylamino)cyclopent-3-ene-1,3-dicarboxylate (21d)
A yellow oil (0.163 g, 81%), 1 
Rac-3-Ethyl 1-methyl 1-(4-hydroxybenzylamino)cyclopent-3-ene-1,3-dicarboxylate (21e)
A yellow oil (0.104 g, 69%), 1 
Representative procedure for hydrolysis of compound 21
Compound 21a (0.106 g, 0.35 mmol) in 10% aq. HCl (3 mL) was heated at 80 o C for 16 h. After cooling, the reaction mixture was diluted with water (2 mL) and washed with ether (5 mL). The water was removed under reduced pressure to give the HCl salt of 22a as a white solid (102 mg, 98%). 1-(Benzylamino)cyclopent-3-ene-1,3-dicarboxylic acid (22a) defined as 100%. Glutamate and amino acids were dissolved and diluted in water.
Rac-
Concentration-response curves were drawn on a logarithmic scale. Sigmoidal curves of best fit were calculated by nonlinear regression analysis using GraphPad software (San Diego, CA). The pIC 50 -value referred to the concentration of a compound producing half the maximum response.
X-ray crystallographic data
Single crystal X-ray diffraction data were collected at 150 K (8b,7c) or 298 K (8a) on a Bruker Smart diffractometer using Mo-Kα radiation (λ=0.71073 Å). Following solution by direct methods, the structures were refined against F 2 with full-matrix least-squares using the program SHELXL-97 15 . All hydrogen atoms were added at calculated positions and refined by use of riding models with isotropic displacement parameters based on those of the parent atoms. Except for the minor components of the disordered atoms in (8b), anisotropic displacement parameters were employed throughout for the non- Table 4 Isolated yields (%) of compounds 21 and 22. Table 5 Agonist and antagonist activities of synthesised compounds. Table 1 Isolated yields (%) of compounds 7 and 8. Table 2 Isolated yields (%) of compounds 9 and 10. 
